|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM016775619 |
| 003 |
DE-627 |
| 005 |
20250124223739.0 |
| 007 |
tu |
| 008 |
231221s1990 xx ||||| 00| ||jpn c |
| 028 |
5 |
2 |
|a pubmed25n0056.xml
|
| 035 |
|
|
|a (DE-627)NLM016775619
|
| 035 |
|
|
|a (NLM)1696063
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a jpn
|
| 100 |
1 |
|
|a Ishihara, Y
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Clinical study of tumor markers in prostatic cancer
|
| 264 |
|
1 |
|c 1990
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 05.09.1990
|
| 500 |
|
|
|a Date Revised 19.11.2015
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a We measured prostatic acid phosphatase (PAP), gamma-seminoprotein (gamma-Sm) and prostatic specific antigen (PSA) levels simultaneously in the serum of 52 patients with untreated prostatic cancer and 44 patients with benign prostatic hypertrophy to assess the clinical usefulness of these tumor markers. PAP and PSA were measured by radioimmunoassay and gamma-Sm by enzyme immunoassay. The positive rates of PAP, gamma-Sm and PSA in patients with prostatic cancer were 50.0, 61.5 and 69.2%, respectively, and those in patients with benign prostatic hypertrophy were 11.4, 13.6 and 13.6%, respectively. In patients with early stage prostatic cancer (stage A and B), the positive rates of PAP, gamma-Sm and PSA were 20.8, 41.7 and 54.2%. The efficiency of PSA was the highest among the three markers. The positive rate of the combination assay of PAP and PSA, that of gamma-Sm and PSA and that of PAP, gamma-Sm and PSA were slightly higher than that of the PSA assay alone. However, the efficiency of the PSA assay alone was higher than that of any combination. No significant correlation was found between histopathological grade and the level of each tumor marker. A significant correlation was found between PAP and gamma-Sm (r = 0.68, P less than 0.001), and between PAP and PSA (r = 0.61, P less than 0.001), but there was no correlation between gamma-Sm and PSA. These results suggest that PSA is the most useful marker and the combination assay of multiple markers is not so advantageous, at least for screening of prostatic cancer
|
| 650 |
|
4 |
|a English Abstract
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Antigens, Neoplasm
|2 NLM
|
| 650 |
|
7 |
|a Biomarkers, Tumor
|2 NLM
|
| 650 |
|
7 |
|a Prostatic Secretory Proteins
|2 NLM
|
| 650 |
|
7 |
|a Proteins
|2 NLM
|
| 650 |
|
7 |
|a Seminal Plasma Proteins
|2 NLM
|
| 650 |
|
7 |
|a beta-microseminoprotein
|2 NLM
|
| 650 |
|
7 |
|a Acid Phosphatase
|2 NLM
|
| 650 |
|
7 |
|a EC 3.1.3.2
|2 NLM
|
| 650 |
|
7 |
|a Prostate-Specific Antigen
|2 NLM
|
| 650 |
|
7 |
|a EC 3.4.21.77
|2 NLM
|
| 700 |
1 |
|
|a Fukagai, T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ohta, K
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hiromoto, Y
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hiramori, M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Torii, T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Higaki, Y
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Imamura, K
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Hinyokika kiyo. Acta urologica Japonica
|d 1962
|g 36(1990), 4 vom: 01. Apr., Seite 425-31
|w (DE-627)NLM012631779
|x 0018-1994
|7 nnas
|
| 773 |
1 |
8 |
|g volume:36
|g year:1990
|g number:4
|g day:01
|g month:04
|g pages:425-31
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2003
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2010
|
| 912 |
|
|
|a GBV_ILN_2012
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 36
|j 1990
|e 4
|b 01
|c 04
|h 425-31
|